OE33 Cells

OE33 is a human oesophageal adenocarcinoma cell line derived from a primary tumor associated with Barrett’s oesophagus. This cell line is extensively used in research to explore the molecular biology and therapeutic responses of oesophageal adenocarcinoma, particularly in the context of Barrett’s oesophagus progression. OE33 provides a relevant model for understanding the pathogenesis of this cancer, which has been increasing in incidence and is associated with poor prognosis in advanced stages.

OE33 cells display epithelial morphology and grow adherently under standard culture conditions. The cell line is characterized by molecular features typical of oesophageal adenocarcinoma, including mutations and dysregulated pathways involved in tumorigenesis, such as p53 and HER2/neu signaling. OE33 is particularly useful for investigating cellular responses to therapeutic interventions targeting HER2/neu and other pathways implicated in cancer progression and resistance. This cell line also serves as a tool for studying the interactions between tumor cells and their microenvironment, as well as mechanisms of metastasis and immune evasion.

In preclinical research, OE33 is widely employed in drug screening to evaluate the efficacy of chemotherapy, targeted therapies, and novel treatment combinations aimed at improving outcomes for oesophageal adenocarcinoma. Additionally, the cell line is used in xenograft models to assess tumorigenicity and therapeutic responses in vivo. OE33’s clinical relevance and molecular characteristics make it an invaluable resource for advancing our understanding of oesophageal adenocarcinoma and developing effective treatments for this aggressive disease.